Polaris Capital Management LLC Has $34.68 Million Stock Position in Gilead Sciences, Inc. $GILD

Polaris Capital Management LLC reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 312,400 shares of the biopharmaceutical company’s stock after selling 12,500 shares during the quarter. Gilead Sciences accounts for about 2.3% of Polaris Capital Management LLC’s holdings, making the stock its 18th biggest holding. Polaris Capital Management LLC’s holdings in Gilead Sciences were worth $34,676,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Brighton Jones LLC grew its holdings in shares of Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Bison Wealth LLC bought a new stake in shares of Gilead Sciences during the fourth quarter worth $215,000. Integrity Alliance LLC. acquired a new position in shares of Gilead Sciences during the first quarter worth $210,000. TrueWealth Advisors LLC lifted its stake in shares of Gilead Sciences by 9.0% in the 2nd quarter. TrueWealth Advisors LLC now owns 2,530 shares of the biopharmaceutical company’s stock valued at $281,000 after acquiring an additional 209 shares during the last quarter. Finally, RDA Financial Network boosted its holdings in shares of Gilead Sciences by 5.1% during the 2nd quarter. RDA Financial Network now owns 2,129 shares of the biopharmaceutical company’s stock valued at $236,000 after acquiring an additional 103 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In related news, Director Kelly A. Kramer sold 2,805 shares of the firm’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $127.10, for a total transaction of $356,515.50. Following the completion of the sale, the director owned 1,339 shares of the company’s stock, valued at $170,186.90. This trade represents a 67.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $124.83, for a total value of $1,248,300.00. Following the completion of the transaction, the chief executive officer directly owned 566,698 shares in the company, valued at approximately $70,740,911.34. This trade represents a 1.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 136,257 shares of company stock worth $16,855,192 over the last quarter. 0.27% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on GILD shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $135.00 target price on shares of Gilead Sciences in a report on Friday, October 31st. The Goldman Sachs Group upped their price objective on Gilead Sciences from $108.00 to $110.00 and gave the company a “neutral” rating in a research note on Friday, October 31st. Mizuho lifted their target price on shares of Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a research report on Friday, November 21st. Argus upped their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Finally, Truist Financial began coverage on shares of Gilead Sciences in a research note on Monday, November 24th. They set a “buy” rating and a $140.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $133.20.

Gilead Sciences Trading Up 1.2%

NASDAQ:GILD opened at $122.60 on Tuesday. Gilead Sciences, Inc. has a 52 week low of $89.02 and a 52 week high of $128.70. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The firm’s fifty day moving average is $123.28 and its 200-day moving average is $117.77. The firm has a market cap of $152.11 billion, a P/E ratio of 19.01, a P/E/G ratio of 0.64 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. Gilead Sciences’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s payout ratio is currently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.